Analysis of an interaction between the soluble vaccinia virus-coded type I interferon (IFN)-receptor and human IFN-alpha 1 and IFN-alpha 2

被引:33
|
作者
Liptakova, H
Kontsekova, E
Alcami, A
Smith, GL
Kontsek, P
机构
[1] SLOVAK ACAD SCI,INST VIROL,BRATISLAVA 84246,SLOVAKIA
[2] UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3RE,ENGLAND
基金
英国惠康基金;
关键词
D O I
10.1006/viro.1997.8527
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The soluble B18R protein coded by vaccinia virus exerts properties of a type I interferon (IFN)-receptor with broad species specificity. We analyzed neutralizing and binding activity of the B18R protein against several recombinant human type I IFNs. The B18R protein inhibited the antiviral potency of IFN-alpha 1, IFN-cua, IFN-alpha 8/1/8, and IFN-omega on human cells. The N-terminal domain of human type I IFN is involved in the high affinity binding to its cellular receptor. To localize the binding domain(s) of IFN with the B18R protein, competition experiments between B18R, and mapped monoclonal antibodies to IFN-alpha 1 and IFN-alpha 2 were performed. Surprisingly, our data indicated that the contact area between the B18R protein and IFN comprised in addition to the N-terminal region of IFN-molecule also its C-terminal portion. We suggest that this different pattern of interaction with a ligand might determine the ability of B18R protein to bind type I IFNs of different species. (C) 1997 Academic Press.
引用
收藏
页码:86 / 90
页数:5
相关论文
共 50 条
  • [2] INTERFERON-ALPHA (IFN-ALPHA) SIGNALING IN CELLS EXPRESSING THE VARIANT FORM OF THE TYPE-I IFN RECEPTOR
    COLAMONICI, OR
    DOMANSKI, P
    KROLEWSKI, JJ
    FU, XY
    REICH, NC
    PFEFFER, LM
    SWEET, ME
    PLATANIAS, LC
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1994, 269 (08) : 5660 - 5665
  • [3] IFN-Alpha Kinoid: A Promising Vaccine against Type 1 Diabetes Targeting IFN-alpha in NOD Mice
    Caillot, Noemie
    Colaone, Fabien
    Bertrand, Romain
    Da Silva, Jennifer
    Hamdi, Samir
    Bonnefoy, Jonathan
    Lehuen, Agnes
    Boitard, Boitard F.
    Grouard-Vogel, Geraldine
    [J]. DIABETES, 2019, 68
  • [4] Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM)
    Zervas, K
    Pouli, A
    Perifanis, V
    Papanastasiou, K
    Chatziyianni, M
    Mitsouli, C
    Maniatis, A
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 1996, 57 (02) : 142 - 148
  • [5] A MONOCLONAL-ANTIBODY TO RECOMBINANT HUMAN IFN-ALPHA RECEPTOR INHIBITS BIOLOGIC ACTIVITY OF SEVERAL SPECIES OF HUMAN IFN-ALPHA, IFN-BETA, AND IFN-OMEGA - DETECTION OF HETEROGENEITY OF THE CELLULAR TYPE-I IFN RECEPTOR
    BENOIT, P
    MAGUIRE, D
    PLAVEC, I
    KOCHER, H
    TOVEY, M
    MEYER, F
    [J]. JOURNAL OF IMMUNOLOGY, 1993, 150 (03): : 707 - 716
  • [6] AMINO-ACIDS RESIDUES OF IFN-ALPHA RESPONSIBLE FOR RECOGNITION OF HUMAN IFN-ALPHA RECEPTOR AND FOR TRIGGERING BIOLOGICAL EFFECTS
    SHAFFERMAN, A
    VELAN, B
    COHEN, S
    LEITNER, M
    GROSFELD, H
    [J]. JOURNAL OF INTERFERON RESEARCH, 1987, 7 (06): : 762 - 762
  • [7] The novel type IFN-delta is neutralized by vaccinia virus-coded type I IFN-receptor
    Vancoval, I
    La Bonnardiere, C
    Kontsek, P
    [J]. EUROPEAN CYTOKINE NETWORK, 1998, 9 (03) : 303 - 303
  • [8] MUTAGENESIS OF BOIFN AS A TOOL FOR IDENTIFICATION OF IFN-ALPHA EPITOPES INTERACTING WITH THE SPECIFIC IFN-ALPHA CELL-RECEPTOR
    SHAFFERMAN, A
    VELAN, B
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 1986, : 234 - 234
  • [9] SOLUBLE AND MEMBRANE-ANCHORED FORMS OF THE HUMAN IFN-ALPHA/BETA RECEPTOR
    NOVICK, D
    COHEN, B
    TAL, N
    RUBINSTEIN, M
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 1995, 57 (05) : 712 - 718
  • [10] TREATMENT OF BEHCET'S DISEASE (BD) WITH INTERFERON-ALPHA (IFN-ALPHA) - A PRADOXON? REVIEW OF THE LITERATURE ON MECHANISMS OF ACTION OF IFN-ALPHA
    Koetler, Ina
    Zierhul, Manfred
    Deuter, Christoph
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (04) : S30 - S30